Fig. 4. An Aβ₄₂ neutralising antibody prevents obesity-induced impairment of cardiac relaxation.

a schematic of experiment where mice fed a high fat diet (HFD) for 4 months and were simultaneously administered a control antibody or an Aβ₄₂ neutralising antibody (3D6) once weekly. Analysis of cardiac function and morphology was performed at the beginning and end of the experiment. b total (n = 12 and 9/group respectively), and; c, free (n = 9 and 8/group respectively) Aβ₄₂ in plasma of mice administered control or 3D6 antibodies (unpaired t-test). d body weight of mice administered control or 3D6 antibodies (n = 12/group). e deceleration time in mice prior to and after 4 months of high-fat feeding and antibody administration (two-way repeated measures ANOVA (time P = 0.0140, F(1,20) = 7.257) and Sidak’s multiple comparisons test P.adjusted; n = 12 and 10/group respectively). f estimated left ventricle (LV) mass in mice prior to and after 4 months of high-fat feeding and antibody administration (two-way repeated measures ANOVA (time P = 0.0010, F(1,20) = 14.93) and Sidak’s multiple comparisons test P.adjusted; n = 11/group). All data are mean ± SEM. Statistical tests are two-tailed. Source data are provided in the Source Data file. Elements of a are created with BioRender.com.